Katherine Eban Discusses Her Just-Published Work, "Bottle of Lies, The Inside Story of the Generic Drug Boom" (July 17th)
www.thehealthcarepolicypodcast.com
Listen now (40 mins) | Listen Now Nine in 10 prescriptions are today filled using a generic drug saving Americans tens of billions annually. A significant amount of generic drugs, along with active ingredients in all drugs, are manufactured overseas. However, how safely or to what quality standards are these ingredients and generics produced? Bottle of Lies, published in May, tells the story of appalling practices foreign generic manufacturers use to produce these drugs at the most minimal cost. The work moreover provides a detailed account of Ranbaxy, the former India-based generic manufacturer that after eight years of investigation was fined a then record amount,$500 million, for significant fraud. The work questions or brings to serious doubt the FDA's ability to adequately inspect overseas generic manufacturers ensuring these drugs are safe for consumption in the US or around the world. Listeners may recall I interviewed coauthor Paul Weinberg in September 2017 concerning his related work, Blood On Their Hands, How Greedy Companies, Inept Bureaucracy and Bad Science Killed Thousands of Hemophiliacs and Rosemary Gibson this past December concerning her related, China Rx, Exposing the Risk of America’s Dependence on China for Medicine.
Katherine Eban Discusses Her Just-Published Work, "Bottle of Lies, The Inside Story of the Generic Drug Boom" (July 17th)
Katherine Eban Discusses Her Just-Published…
Katherine Eban Discusses Her Just-Published Work, "Bottle of Lies, The Inside Story of the Generic Drug Boom" (July 17th)
Listen now (40 mins) | Listen Now Nine in 10 prescriptions are today filled using a generic drug saving Americans tens of billions annually. A significant amount of generic drugs, along with active ingredients in all drugs, are manufactured overseas. However, how safely or to what quality standards are these ingredients and generics produced? Bottle of Lies, published in May, tells the story of appalling practices foreign generic manufacturers use to produce these drugs at the most minimal cost. The work moreover provides a detailed account of Ranbaxy, the former India-based generic manufacturer that after eight years of investigation was fined a then record amount,$500 million, for significant fraud. The work questions or brings to serious doubt the FDA's ability to adequately inspect overseas generic manufacturers ensuring these drugs are safe for consumption in the US or around the world. Listeners may recall I interviewed coauthor Paul Weinberg in September 2017 concerning his related work, Blood On Their Hands, How Greedy Companies, Inept Bureaucracy and Bad Science Killed Thousands of Hemophiliacs and Rosemary Gibson this past December concerning her related, China Rx, Exposing the Risk of America’s Dependence on China for Medicine.